These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19904263)

  • 1. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma.
    Reardon DA; Dresemann G; Taillibert S; Campone M; van den Bent M; Clement P; Blomquist E; Gordower L; Schultz H; Raizer J; Hau P; Easaw J; Gil M; Tonn J; Gijtenbeek A; Schlegel U; Bergstrom P; Green S; Weir A; Nikolova Z
    Br J Cancer; 2009 Dec; 101(12):1995-2004. PubMed ID: 19904263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
    Reardon DA; Egorin MJ; Quinn JA; Rich JN; Gururangan S; Vredenburgh JJ; Desjardins A; Sathornsumetee S; Provenzale JM; Herndon JE; Dowell JM; Badruddoja MA; McLendon RE; Lagattuta TF; Kicielinski KP; Dresemann G; Sampson JH; Friedman AH; Salvado AJ; Friedman HS
    J Clin Oncol; 2005 Dec; 23(36):9359-68. PubMed ID: 16361636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
    Reardon DA; Egorin MJ; Desjardins A; Vredenburgh JJ; Beumer JH; Lagattuta TF; Gururangan S; Herndon JE; Salvado AJ; Friedman HS
    Cancer; 2009 May; 115(10):2188-98. PubMed ID: 19248046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
    Reardon DA; Desjardins A; Vredenburgh JJ; Herndon JE; Coan A; Gururangan S; Peters KB; McLendon R; Sathornsumetee S; Rich JN; Lipp ES; Janney D; Friedman HS
    Cancer; 2012 Oct; 118(19):4759-67. PubMed ID: 22371319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
    Desjardins A; Quinn JA; Vredenburgh JJ; Sathornsumetee S; Friedman AH; Herndon JE; McLendon RE; Provenzale JM; Rich JN; Sampson JH; Gururangan S; Dowell JM; Salvado A; Friedman HS; Reardon DA
    J Neurooncol; 2007 May; 83(1):53-60. PubMed ID: 17245623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients.
    Pursche S; Schleyer E; von Bonin M; Ehninger G; Said SM; Prondzinsky R; Illmer T; Wang Y; Hosius C; Nikolova Z; Bornhäuser M; Dresemann G
    Curr Clin Pharmacol; 2008 Sep; 3(3):198-203. PubMed ID: 18781906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
    Reardon DA; Norden AD; Desjardins A; Vredenburgh JJ; Herndon JE; Coan A; Sampson JH; Gururangan S; Peters KB; McLendon RE; Norfleet JA; Lipp ES; Drappatz J; Wen PY; Friedman HS
    J Neurooncol; 2012 Jan; 106(2):409-15. PubMed ID: 21938530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
    Reardon DA; Desjardins A; Vredenburgh JJ; Sathornsumetee S; Rich JN; Quinn JA; Lagattuta TF; Egorin MJ; Gururangan S; McLendon R; Herndon JE; Friedman AH; Salvado AJ; Friedman HS
    Neuro Oncol; 2008 Jun; 10(3):330-40. PubMed ID: 18359865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series.
    Dresemann G
    Ann Oncol; 2005 Oct; 16(10):1702-8. PubMed ID: 16033874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
    Dresemann G; Weller M; Rosenthal MA; Wedding U; Wagner W; Engel E; Heinrich B; Mayer-Steinacker R; Karup-Hansen A; Fluge O; Nowak A; Mehdorn M; Schleyer E; Krex D; Olver IN; Steinbach JP; Hosius C; Sieder C; Sorenson G; Parker R; Nikolova Z
    J Neurooncol; 2010 Feb; 96(3):393-402. PubMed ID: 19688297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
    Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD
    Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas.
    Shah GD; Silver JS; Rosenfeld SS; Gavrilovic IT; Abrey LE; Lassman AB
    J Neurooncol; 2007 Nov; 85(2):217-22. PubMed ID: 17594055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma.
    Paulsson J; Lindh MB; Jarvius M; Puputti M; Nistér M; Nupponen NN; Paulus W; Söderberg O; Dresemann G; von Deimling A; Joensuu H; Ostman A; Hasselblatt M
    Int J Cancer; 2011 Apr; 128(8):1981-8. PubMed ID: 20589679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
    Reardon DA; Vredenburgh JJ; Desjardins A; Peters K; Gururangan S; Sampson JH; Marcello J; Herndon JE; McLendon RE; Janney D; Friedman AH; Bigner DD; Friedman HS
    J Neurooncol; 2011 Jan; 101(1):57-66. PubMed ID: 20443129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.
    Schneider BJ; Kalemkerian GP; Ramnath N; Kraut MJ; Wozniak AJ; Worden FP; Ruckdeschel JC; Zhang X; Chen W; Gadgeel SM
    Clin Lung Cancer; 2010 Jul; 11(4):223-7. PubMed ID: 20630823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.
    Maurel J; Martins AS; Poveda A; López-Guerrero JA; Cubedo R; Casado A; Martínez-Trufero J; Ramón Ayuso J; Lopez-Pousa A; Garcia-Albeniz X; Garcia del Muro X; de Alava E
    Cancer; 2010 Aug; 116(15):3692-701. PubMed ID: 20564079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Imatinib combination therapies--the new CML Study 4].
    Helmann R; Berger U; Engelich G
    Dtsch Med Wochenschr; 2002 Oct; 127(42):224-6. PubMed ID: 12430568
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
    Cortes J; Jabbour E; Daley GQ; O'Brien S; Verstovsek S; Ferrajoli A; Koller C; Zhu Y; Statkevich P; Kantarjian H
    Cancer; 2007 Sep; 110(6):1295-302. PubMed ID: 17623836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
    JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.